{
  "id": "resp_01ac87ef0b10bebc00693c8d6ae89481908804fdd84f414fc4",
  "object": "response",
  "created_at": 1765576042,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_01ac87ef0b10bebc00693c8d6b5b4481908a1933fc0459d2e7",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_01ac87ef0b10bebc00693c8d6d05c4819086dda0cf3bc962f7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrialsregister.eu CDK12 inhibitor \"triple-negative\""
      }
    },
    {
      "id": "rs_01ac87ef0b10bebc00693c8d6ebf908190ba185bbb8780aaac",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_01ac87ef0b10bebc00693c8d74028c81908977aaa35179ea52",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrialsregister.eu CDK12 \"triple negative\""
      }
    },
    {
      "id": "rs_01ac87ef0b10bebc00693c8d762ffc819085f8c8bc1e611f21",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_01ac87ef0b10bebc00693c8d7a3b608190b8e5088aa6af8702",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrialsregister.eu/ctr-search/trial CDK12"
      }
    },
    {
      "id": "rs_01ac87ef0b10bebc00693c8d7cfd848190b2583eabe210cd74",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_01ac87ef0b10bebc00693c8d80861c8190a216024679dc16a0",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrialsregister.eu \"cyclin-dependent kinase 12\" \"triple\""
      }
    },
    {
      "id": "rs_01ac87ef0b10bebc00693c8d8318ac8190afeaafcfbfc1db01",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_01ac87ef0b10bebc00693c8d8cc15c8190944fdef44f275b3f",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004930-39/ES"
      }
    },
    {
      "id": "rs_01ac87ef0b10bebc00693c8d8e1cfc81909d9a671127764cb9",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_01ac87ef0b10bebc00693c8d911fa481908ee3e9e6a174c62b",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "EudraCT",
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000324-29/ES"
      }
    },
    {
      "id": "rs_01ac87ef0b10bebc00693c8d9389788190a20311b6fff7c3cf",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_01ac87ef0b10bebc00693c8d9515bc8190b20642ddedacfd43",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003608-30/GB"
      }
    },
    {
      "id": "rs_01ac87ef0b10bebc00693c8d9753e08190891c207192242f4a",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_01ac87ef0b10bebc00693c8db1974c8190a97843c42da5c61f",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 607,
              "start_index": 504,
              "title": "\n\t\t    \n                \n                \n                \n                    Clinical Trials Register\n                \n            \n\t\t",
              "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004930-39/ES"
            },
            {
              "type": "url_citation",
              "end_index": 1152,
              "start_index": 1049,
              "title": "\n\t\t    \n                \n                \n                \n                    Clinical Trials Register\n                \n            \n\t\t",
              "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000324-29/ES"
            },
            {
              "type": "url_citation",
              "end_index": 1788,
              "start_index": 1685,
              "title": "\n\t\t    \n                \n                \n                \n                    Clinical Trials Register\n                \n            \n\t\t",
              "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003608-30/GB"
            }
          ],
          "logprobs": [],
          "text": "- **Clinical trials — “A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo … Triple-Negative Breast Cancer (PRESERVE 2)”**\n  - URL: `https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004930-39/ES`\n  - Direct quote snippets:\n    - “EudraCT Number:2020-004930-39”\n    - “Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Triple-Negative Breast Cancer (TNBC) (PRESERVE 2)”\n    - “A.5.2 US NCT (ClinicalTrials.gov registry) number NCT04799249” ([clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004930-39/ES))\n\n- **Clinical trials — “A Phase I/IIa Trial With BMS-986158 … (BET) Proteins … Selected Advanced Solid Tumors”**\n  - URL: `https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000324-29/ES`\n  - Direct quote snippets:\n    - “A.2 EudraCT number 2015-000324-29”\n    - “A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins,”\n    - “E.1.2 Term Triple negative breast cancer” ([clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000324-29/ES))\n\n- **Clinical trials — “A Phase II, Multi Center Study of BGB324 in combination with Pembrolizumab … Triple Negative Breast Cancer (TNBC) …”**\n  - URL: `https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003608-30/GB`\n  - Direct quote snippets:\n    - “EudraCT Number:2016-003608-30”\n    - “BGB324 in combination with Pembrolizumab in Patients with Previously Treated, Locally Advanced and Unresectable or Mestastic Triple Negative Breast Cancer (TNBC)”\n    - “A.5.2 US NCT (ClinicalTrials.gov registry) number NCT03184558” ([clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003608-30/GB))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 34058,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 4047,
    "output_tokens_details": {
      "reasoning_tokens": 3532
    },
    "total_tokens": 38105
  },
  "user": null,
  "metadata": {}
}